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Context 
Anemia and thyroid dysfunction often co-occur and both increase with age. Human data on 
the relationship between thyroid disease and anemia are scarce. 
Objective 
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To investigate the cross-sectional and longitudinal associations between clinical thyroid 
status and anemia.  
Design  
Individual participant data meta-analysis. 
Setting 
Sixteen cohorts participating in the Thyroid Studies Collaboration (n=42 162). 
Main outcome measures 
Primary outcome measure was anemia (hemoglobin <130g/L in men and <120 g/L in 
women).  
Results 
Cross-sectionally, participants with abnormal thyroid status had an increased risk of having 
anemia compared with euthyroid participants (overt hypothyroidism, pooled odds ratio 1.84 
[95% CI: 1.35-2.50], subclinical hypothyroidism 1.2 [1.02-1.43], subclinical 
hyperthyroidism 1.27 [1.03-1.57], overt hyperthyroidism 1.69 [1.00-2.87]). Hemoglobin 
levels were lower in all groups compared to participants with euthyroidism. 
In the longitudinal analyses (n=25,466 from 14 cohorts), the pooled hazard ratio for the risk 
of development of anemia was 1.38 [95% CI: 0.86-2.20] for overt hypothyroidism, 1.18 
[1.00-1.38] for subclinical hypothyroidism, 1.15 [0.94-1.42] for subclinical hyperthyroidism 
and 1.47 [0.91-2.38] for overt hyperthyroidism. Sensitivity analyses excluding thyroid 
medication or high levels of C-reactive protein yielded similar results. No differences in 
mean annual change in hemoglobin levels were observed between the thyroid hormone status 
groups. 
Conclusion 
Higher odds of having anemia were observed in both participants with hypothyroid function 
and hyperthyroid function. In addition, reduced thyroid function at baseline showed a trend of 
increased risk of developing anemia during follow-up. It remains to be assessed in a 
randomized controlled trial whether treatment is effective in reducing anemia.  
This individual participant data meta-analysis found higher odds of having anemia in both participants 
with decreased and increased thyroid function. 
Introduction 
Thyroid diseases and anemia are common disorders and their prevalences increase with age 
(1-4). Hypothyroidism and anemia can each cause non-specific symptoms of ill health like 
fatigue and both lead to decreased quality of life.The combination of anemia and abnormal 
thyroid function may therefore be accompanied by serious morbidity and further effects on 
quality of life.  
The co-occurrence of anemia and hypothyroidism is not o ly a challenging diagnostic 
problem in allocating symptoms to one of the diseases, but may also point to a causal 
relationship between thyroid disease and anemia (5). Indeed, relationships between thyroid 
disease and anemia have already been documented in experimental animal studies in the 
distant past (5). For instance, hypophysectomized mam als were found to have decreased 
red blood cell counts that corrected after administration of thyroid hormones (6, 7). 
Additionally, mice deficient in the thyroid hormone r ceptor TRα have been found to have 
decreased hematocrit values (8). 
However, human data regarding relationships between thyroid disease and hematologic 
anomalies are scarce. Researchers investigating potential altered erythropoiesis as a result of 
thyroid dysfunction found red cell abnormalities and a reduced proliferative potential of 
hematopoietic progenitor cells in both patients with hypo- and hyperthyroidism, but the total 
number of studied participants was low (9, 10).  
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In addition, a higher prevalence of anemia was ident fi d in older male patients with 
subclinical hypothyroidism(11) and in patients with clinical hypothyroidism (12), but 
incidence estimates were not available due to the cross-sectional study design. Additionally, a 
rise of thyroid hormone levels or a decrease in levels of TSH within the reference ranges was 
associated with higher erythropoietic activity (13) but the low number of studied participants 
precluded stratification by hyperthyroid subgroups. In one population-based cohort both 
hypothyroidism and hyperthyroidism was associated with decreased hemoglobin in cross-
sectional analyses but not in longitudinal analyses (14). 
Clinical experimental evidence on the causal relation between low thyroid function and 
anemia is currently limited to a number of small case series, in which treatment of 
hypothyroidism with levothyroxine resulted in a significant increase in hemoglobin and 
resolution of anemia (12, 15, 16). Alternatively, and in line with the observational data, in a 
cohort of hyperthyroid patients a high prevalence of anemia was found, which returned to 
normal following antithyroid therapy (17).  
Despite the myriad of smaller studies hinting at a potential relationship between thyroid 
dysfunction and anemia, methodologically sound pooled estimates drawn from large and 
representative populations are missing. With  the current study we sought to determine the 
association between thyroid hormone status and anemi  in cross-sectional and longitudinal 
analyses by performing an individual participant data meta-analysis on data from 16 
independent observational cohort studies participating in the Thyroid Studies Collaboration.  
Methods 
Study population 
We performed an individual participant data meta-anlysis of cohorts participating in the 
Thyroid Studies Collaboration. The cohorts are summarized in table 1 and are described 
elsewhere in detail (2, 18-20). For the current project we included the 16 cohorts in which 
thyroid function tests and hemoglobin were measured at baseline. 
Anemia 
Anemia was defined according to the World Health Organization (WHO) criteria 
(hemoglobin concentration <130 g/L in men and <120 g/L in women) (21). In 14 cohorts, a 
follow-up measurement of hemoglobin was available.  
Thyroid function 
TSH and free T4 concentrations were measured at baseline in all cohorts. Cohort specific cut-
off values were applied for free T4 concentrations (Appendix table 1). Participants with a 
TSH level of 0.45 to 4.5 mIU/L were categorized as euthyroid. Overt hypothyroidism was 
defined as a TSH level above 4.5 mIU/L in combination with reduced free T4 concentration. 
Subclinical hypothyroidism was defined as TSH level above 4.5 mIU/L in combination with 
a normal free T4 concentration. A TSH level below 0.45 mIU/L with normal free T4 levels 
was defined as subclinical hyperthyroidism. Overt hyperthyroidism was defined as TSH level 
below 0.45 mIU/L with an elevated free T4 concentration (2).  
Statistical analyses 
We performed a two-stage individual participant data meta-analysis to allow for consistent 
definitions and analyses across the cohorts, increased nalytical flexibility and decreased 
complexity of the analyses (18, 22-25). In the first step, the cross-sectional and longitudinal 
associations between thyroid hormone status and anemi  in each study cohort were estimated 
separately from supplied original study datasets wih data on the participant level. In the 
second step all effect estimates found in step 1 were pooled using random-effects models 
(DerSimonian and Laird) with inverse variance weighting.  
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For the cross-sectional association between thyroid h rmone status and anemia at 
baseline, logistic regression models were constructed. Prospectively, we investigated the risk 
of developing anemia during follow-up using Cox regression models; participants with pre-
existing anemia were excluded. The analyses were bas d on the thyroid function category at 
baseline. If a new case of anemia was identified, it was assumed that the anemia had 
developed halfway through the follow-up period. 
Thyroid status was included as a categorical variable (overt hypothyroidism, subclinical 
hypothyroidism, subclinical hyperthyroidism, overt hyperthyroidism), with euthyroidism as 
the reference group. All models were adjusted for age nd sex. A p value for trend was 
obtained for both overt and subclinical hypothyroid and hyperthyroid categories. Subgroup 
analyses, including calculations of a p value for interaction, were performed separately for 
sex, age groups and ethnicity.  
In sensitivity analyses, we excluded all participants who used antithyroid medication or 
thyroid hormone replacement therapy at baseline or during follow-up. We also compared 
mean hemoglobin levels at baseline between thyroid status groups and differences in mean 
annual change in hemoglobin levels during follow-up between thyroid status groups using 
linear regression models. Additionally we excluded all participants with a high level of C-
reactive protein (CRP, >20 mg/L) as a proxy for chronic inflammatory disease. 
Data analyses were performed using IBM SPSS Statistics Version 23 and Review 
Manager 5.3 from The Cochrane Collaboration. 
Results 
For this study, individual participant data of 56 297 participants from 16 different cohorts 
participating in the Thyroid Studies Collaboration were available. At baseline, thyroid 
function (TSH and fT4) and hemoglobin measurements were available from 42 162 
participants, of whom 459 (1.1%) had overt hypothyroidism, 2930 (6.9%) had subclinical 
hypothyroidism, 36 081 (85.6%) were euthyroid, 2386 (5.7%) had subclinical 
hyperthyroidism, and 306 (0.7%) had overt hyperthyroidism.  
Baseline characteristics of the cohorts are presentd i  Table 1. The overall median age of 
each cohort ranged from 46 to 85 years and the overall percentage of women was 51.0%. 
More detailed information about the study participants is presented in Appendix Tables 2 and 
3. The participants excluded because their thyroid function or hemoglobin measurement were 
not available had a median ages ranging from 45 to 84; the percentage of women was 51.5%. 
Cross-sectional analyses 
At baseline 4274 (10.1%) participants had anemia; 15.9% in the overt hypothyroid group 
11.6% in the subclinical hypothyroid group, 9.7% in the euthyroid group, 13.6% in the 
subclinical hyperthyroid group and 11.1% in the overt hyperthyroid group. Participants with 
subclinical or overt hypothyroidism and subclinical or overt hyperthyroidism had increased 
odds of having anemia compared to euthyroid participants (Table 2 and Figure 1). The pooled 
odds ratio for the overt hypothyroid group was 1.84 [95% CI: 1.35-2.50], 1.21 [1.02-1.43] for 
the group with subclinical hypothyroidism, 1.27 [1.03-1.57] for those with subclinical 
hyperthyroidism and 1.69 [1.00-2.87] for those in the overt hyperthyroid group. We observed 
statistically significant trends from euthyroidism to hypothyroidism (i.e. from subclinical 
hypothyroidism to overt hypothyroidism, p=0.01), and from euthyroidism to hyperthyroidism 
(i.e. from subclinical hyperthyroidism to overt hyperthyroidism, p=0.04). When the analyses 
were stratified by sex, we observed no statistically significant differences (all p values for 
interaction>0.05) between men and women, Table 2. Also, no statistically significant 
differences were observed between different age categories or between white, black or Asian 
participants.  
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Longitudinal analyses 
In the longitudinal analyses 25 466 participants from 14 cohorts were included with a median 
follow-up time of 5.7 years (IQR 3.0-9.5). 2423 participants developed anemia during follow-
up (14.9 per 1000 person years), 12.2% in the overt hypothyroid group, 12.0% in the 
subclinical hypothyroid group, 9.2% in the euthyroid group, 10.7% in the subclinical 
hyperthyroid group and 8.7% in the overt hyperthyroid group (Table 3 and Figure 2). The 
pooled hazard ratios for the risk of developing anemia were 1.38 [95% CI: 0.86-2.20] for the 
overt hypothyroid group, 1.18 [1.00-1.38] for the group with subclinical hypothyroidism, 
1.15 [0.94-1.42] for the group with subclinical hyperthyroidism and 1.47 [0.91-2.38] in the 
overt hyperthyroid group. We observed a statistically significant trend from euthyroidism to 
hypothyroidism (p=0.02). No statistically significant trend was observed for euthyroidism to 
hyperthyroidism (p=0.20). When the participants were stratified by sex, age or ethnicity, 
these findings remained unchanged. Associations were more pronounced in those studies 
with a median follow-up ≥ 5 years (Appendix table 4). 
Additional analyses 
Cross-sectionally, hemoglobin levels (as a continuous variable) were lower (mean difference 
between -0.06 and -0.19 g/dL) in all groups compared to participants with euthyroidism 
(Appendix table 5). Prospectively, no differences in mean annual change in hemoglobin 
levels were observed between the thyroid hormone status groups (Appendix table 6). Similar 
results were observed when analyses were stratified on sex. In addition, sensitivity analyses 
excluding participants who used thyroid hormone medication or with high levels of CRP, 
yielded higher odds ratios in line with the unrestricted results but with wider confidence 
intervals (Appendix Table 7 and 8). 
For all main analyses I2 statistics remained below 40% (Appendix Table 9 and 10) and, in 
combination with size and direction of effects, stati ical heterogeneity was deemed low to 
negligible (26). 
Discussion 
In this individual participant data meta-analysis, we observed a cross-sectional relation 
between thyroid function and anemia; higher odds of anemia were observed in both 
participants with overt and subclinical hypothyroidism as well as overt and subclinical 
hyperthyroidism. In addition, reduced thyroid function at baseline showed a trend of 
increased risk of developing anemia during follow-up. The longitudinal association between 
overt and subclinical hyperthyroidism and the risk of developing anemia did not reach 
statistical significance. Prospectively, no differenc s in mean annual change in hemoglobin 
levels were observed between the thyroid hormone status groups.  
The findings in the current individual participant data meta-analysis build on findings 
from earlier studies where thyroid dysfunction was as ociated with abnormal red blood cell 
indices (11-13). In this study thyroid dysfunction, whether overt or subclinical hypo- and 
hypothyroidism, was associated with slightly lower h moglobin levels. Given the small 
difference in hemoglobin levels between thyroid function groups, the contribution of thyroid 
dysfunction on low hemoglobin levels or anemia may be small. It remains to be assessed in a 
randomized controlled trial whether treatment of (subclinical) hypothyroidism is effective in 
reducing anemia to further decide whether the findings are thought to be clinically relevant 
and whether these should influence practice and policies. Christ-Crain and colleagues showed 
that erythropoietin levels increased after thyroxin treatment in patients with subclinical 
hypothyroidism (27). In addition, a number of studies have also shown a beneficial effect of 
thyroid hormone treatment in patients with hypothyroidism on erythropoietin levels (12, 15, 
16).  
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There are numerous types of anemia that can be classified according to whether the 
anemia is primarily the result of blood loss, deficits in the production of healthy erythrocytes 
or by reduced erythrocyte survival. Currently it is unclear what mechanisms exactly allow 
thyroid function and erythropoiesis to be linked pathophysiologically, and how both ends of 
the thyroid disease spectrum might lead to an anemic state.  However, for subclinical and 
overt hyperthyroidism several pathways have been proposed. Hyperthyroidism might be 
associated with anemia via reduced erythrocyte survival due to altered iron metabolism and 
utilization, enhanced oxidative stress and increased haemolysis (28, 29). Thyroid hormones 
stimulate energy metabolism, resulting in an enhanced requirement of oxygen delivery to the 
tissues speeding up destructive processes. 
For subclinical and overt hypothyroidism there is accumulating evidence that indicates 
low thyroid function may be causally related to anemia via deficits in the production of 
healthy erythrocytes, although the underlying mechanisms by which thyroid hormones and 
TSH may lead to anemia are not fully understood (30). Triiodothyronine (T3), thyroxine (T4) 
and thyroid stimulating hormone (TSH), may play a direct role in erythropoiesis (31). For 
instance, both T3 and T4 are involved in the regulation of hematopoiesis by influencing 
erythroid precursor proliferative capacity (32). In addition, a direct β2-adrenergic receptor-
mediated stimulation of red cell precursors by T4 has been shown (33). T4 has also been 
found to stimulate the initiation and completion of hemoglobin protein chains in vitro , and to 
enhance red blood cell formation (5). Thyroid hormones were also shown to promote 
erythropoiesis by increasing the production of erythropoietin by the kidneys (34). 
Furthermore, there is evidence that thyroid hormones affect iron transport and utilisation. 
TSH could affect hematopoiesis by binding to a functional thyrotropin receptor (TSHR), 
which can be found in erythrocytes and some extrathy oidal tissues (10). Another explanation 
for the co-occurrence of low thyroid function and anemia is that there are common causes for 
abnormal thyroid status and anemia. Chronic (inflammatory) diseases, malnutrition and 
malabsorption may all result in reduced thyroid status as an adaptive response to energetic 
deficits. In addition, malnutrition and malabsorption may cause deficiencies of micronutrients 
that are crucial for erythropoiesis, like iron, vitamin B12 and folate, as well as iodine 
deficiency which is crucial for normal thyroid function. Interestingly, iron deficiency, which 
is the most common cause of anemia, was also found to decrease the activity of TPO, an iron-
containing enzyme involved in the synthesis of thyroid hormones (35).  
Strengths of the current individual participant data meta-analysis are the inclusion of 
individual participant data of large cohort studies from across the globe. The availability of 
individual participant data allowed us to choose clini ally relevant categories of thyroid 
function and anemia, to standardize these definitions, and to perform several standardized 
subgroup analyses.  
An individual participant data meta-analysis of well-designed observational studies can 
be considered an important tool in assessing causality. When studying causality, the nine 
considerations of Austin Bradford Hill in 1965 can be used as a checklist (36). In our study, 
many of these considerations are met. Although the individual study cohorts and individual 
subgroups may have been small, we had sufficient power to study the associations in this 
pooled analysis because of the increased combined sample size. Since multiple studies were 
included, we could also study consistency in the results of the different cohorts (e.g. effect 
estimates all pointing in the same direction); the low level of heterogeneity also aids in 
considering a causal relation. In addition, the avail bility of the individual participant data 
allowed us to define identical subgroups for each study in a biological gradient, from overt 
hypothyroidism to overt hyperthyroidism. The availab ity of prospective observational data 
is also in compliance with the fourth consideration of temporality; in 14 studies a baseline 
measurement of the determinant (thyroid function) and (baseline and) follow-up 
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measurements of the outcome of interest (hemoglobin) were available. Therefore, our pooled 
analysis of observational studies satisfies multiple criteria of Bradford Hill. However, it 
remains to be assessed in a well-designed randomized controlled trial with a considerable 
number of participants with (subclinical) hypothyroidism, if treatment is effective in reducing 
anemia. Further analysis of the data from two well-d signed RCT’s for subclinical 
hypothyroidism in older persons (TRUST & IEMO Thyroid Trial (37, 38)) could be a first 
attempt at uncovering the clinical relevance of thyroid influences on hemoglobin levels. 
Some limitations of this study have to be acknowledged as well. First, a limitation of this 
pooled analysis is that TSH and free T4 were only measured once at baseline. Because 
subclinical hypothyroidism has been shown to normalize in one third of cases (39), in 
guidelines it is often recommended that measurements of these parameters are repeated. 
Unfortunately, repeated TSH and free T4 measurements were not available in many cohorts. 
Erroneously classifying euthyroid patients on the basis of one measurement may have led to 
an underestimation of the associations found. Second, the statistical power was more limited 
in the longitudinal models than in the baseline, cross-sectional analysis. The association 
between overt and subclinical hyperthyroidism and the risk of developing anemia did not 
reach statistical significance, but the results of the longitudinal analyses followed a similar 
pattern.  Third, we did not apply age-adjusted reference ranges as per current consensus and 
usual practice. However, evidence in favour of age-sp cific TSH reference ranges is starting 
to accumulate (40), so too is evidence to the contrary (41-43). This is an important topic of 
future research. Fourth, we performed sensitivity analyses excluding participants with high 
CRP levels as a proxy for chronic diseases that might predispose to anemia, but this only 
excluded diseases associated with inflammation. Particularly in the group of participants with 
subclinical hypothyroidism the possibility of the presence of non-thyroidal illness cannot be 
fully excluded. As a result, possible residual errors caused by residual bias and confounding 
may have deflated the results. Unfortunately information on additional potential confounding 
factors, like thyroid medication dose titrations, other diseases relating to anemia (cancer, 
chronic kidney disease, leukemia, gastric ulcers, arthritis or COPD), menopausal state, non-
thyroidal illness, concomitant medications and iron or vitamin supplements, was not available 
for most cohorts.  
In conclusion, we observed higher odds of anemia in both participants with hypothyroid 
function and hyperthyroid function. In addition, reduced thyroid function at baseline showed 
a trend of increased risk of developing anemia during follow-up. It remains to be assessed in 
a randomized controlled trial whether treatment of (subclinical) hypothyroidism is effective 
in reducing anemia.  
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Figure 1. The pooled odds ratios of the risk of having anemia at baseline with the 95% 
confidence interval and the p value for trend. Logistic regression models corrected for age 
and sex; reference group is euthyroidism. 
Figure 2. The pooled hazard ratios of developing anemia during follow-up in the thyroid 
function groups with the 95% confidence interval and the p value for trend. Cox regression 
models corrected for age and sex; reference group is euthyroidism.  
Table 1. Baseline characteristics of individuals in included studies (N=42 162)  
Study Study 
population 
Total number of 
participants: 
baseline/follow-
up 
Age, 
Median 
(Range), 
y 
Women 
(%) 
Antithyroid 
or thyroid 
medication 
at baseline 
(%) 
Anemia 
at 
baseline 
(%) 
Anemia 
during 
follow-
up (%) 
Duration 
of 
follow-
up, 
Median 
(IQR), y 
Total 
person 
years 
Total   42 162/25 466 14-103 
22 308 
(52.9)  
1067 (2.5) 
4274 
(10.1) 
2423 
(5.7) 
5.7 (3-
9.5) 
162583 
Bari study Outpatients 
with heart 
failure 
followed up by 
Cardiology 
Department in 
Bari, Italy 
337/206 66 (21-
92) 
78 
(20.5) 
23 (6.8) 69 
(20.5) 
30 (8.9) 1.4 (0.7-
1.9) 
273 
BELFRAIL Subjects aged 
80 years and 
older in three 
well-
circumscribed 
areas of 
Belgium. 
524/331 84 (80-
100) 
331 
(63.2) 
52 (9.9) 106 
(20.2) 
52 (9.9) 1.6 (1.4-
1.8) 
521 
Busselton 
Health study 
Adults living in 
Busselton, 
Western 
Australia 
2074/1245 51 (17-
90) 
1030 
(49.7) 
27 (1.3) 76 (3.7) 54 (2.6) 14.0 
(14.0-
14.0) 
17164 
Cardiovascular 
Health study 
Community-
dwelling adults 
with Medicare 
eligibility in 4 
US 
3106/2314 71 (64-
100) 
1864 
(60.0) 
0 259 
(8.3) 
321 
(10.3) 
3.0 (3.0-
3.0) 
12552 
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communities. 
EPIC-Norfolk 
study 
Adults aged 45-
79 years living 
in Norfolk, 
England 
13  1/27 59 (40-
78) 
7276 
(54.8) 
NA 1090 
(8.2) 
499 
(3.8) 
4.3 (3.4-
12.3) 
57604 
Health, Aging, 
and Body 
Composition 
study 
Community 
dwelling adults 
aged 70-79 
years with 
Medicare 
eligibility in 2 
US 
communities 
2531/1236 74 (70-
81) 
1305 
(51.6) 
253 (10.0) 384 
(15.2) 
195 
(7.7) 
7.5 (7.5-
7.5) 
8543 
InChianti study Community 
dwelling from 
two small 
towns in 
Tuscany, Italy. 
Invecchiare in 
Chianti, “Aging 
in the Chianti 
Area” 
(InCHIANTI) 
study. 
1200/944 72 (21-
103) 
675 
(56.3) 
30 (2.5) 120 
(10.0) 
177 
(14.8) 
9.0 (6.0-
9.2) 
6958 
Longitudinal 
Aging Study 
Amsterdam 
(LASA)(20) 
Random 
sample of older 
men and 
women (aged 
55-85) in 
Amsterdam, 
Zwolle, and 
Oss, the 
Netherlands. 
766/329 68 (55-
85) 
393 
(51.3) 
14 (1.8) 43 (5.6) 28 (3.7) 3.0 (3.0-
3.1) 
974 
Leiden 85-plus 
Study 
All adults aged 
85 years living 
in Leiden, the 
Netherlands. 
555/397 85 (NA) 368 
(66.3) 
20 (3.6) 158 
(28.5) 
98 
(17.7) 
3.0 (0.5-
5.0) 
1324 
Nagasaki 
Adult Health 
study 
Atomic bomb 
survivors in 
Nagasaki, 
Japan. 
965/753 57 (38-
92) 
578 
(59.9) 
11 (1.1) 179 
(18.5) 
196 
(20.3) 
11.9 
(7.4-
12.0) 
7196 
Pisa cohort Patients 
admitted to 
cardiology  
department in 
Pisa, Italy. 
2259/NA 68 (14-
96) 
785 
(34.7) 
NA 490 
(21.7) 
NA NA NA 
PREVEND 
study 
Inhabitants, 
aged 28–75 
years, of the 
city of 
Groningen, The 
Netherlands. 
934/779 60 (35-
82) 
397 
(42.5) 
NA 106 
(11.3) 
82 (8.8) 5.7 (5.7-
5.7) 
8247 
PROSPER 
study 
Older 
community 
dwelling  adults 
at high 
cardiovascular 
risk in the 
Netherlands, 
Ireland, and 
Scotland. 
5769/5138 75 (69-
83) 
2983 
(51.7) 
256 (4.4) 402 
(7.0) 
203 
(3.5) 
0.25 
(0.25-
0.25) 
1261 
Rotterdam 
Study 
All inhabitants 
of the suburb 
Ommoord in 
Rotterdam, the 
Netherlands, 
aged 55 years 
and over. 
1835/1322 69 (55-
93) 
1135 
(61.9) 
45 (2.5) 109 
(5.9) 
214 
(11.7) 
11.1 
(6.6-
17.4) 
14066 
SHIP(44) Adults living in 
Western 
Pomerania, 
Germany. 
4214/2882 50 (20-
81) 
2139 
(50.8) 
263 (6.2) 589 
(14.0) 
274 
(6.5) 
10.0 
(5.0-
11.0) 
25900 
Whickham 
Survey 
Adults living in 
and near 
1807/NA 46 (18-
93) 
971 
(53.7) 
73 (4.0) 94 (5.2) NA NA NA 
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Newcastle 
upon Tyne, 
England. 
Abbreviations: IQR, interquartile range (25th-75th percentiles); NA, data not available. 
Table 2. The risk of having anemia at baseline according to thyroid hormone status (N=42 
162 from 16 cohorts).  
 Overt 
hypothyroidism 
Subclinical 
hypothyroidism 
Euthyroidism Subclinical 
hyperthyroidism 
Overt 
hyperthyroidism 
N overt hypo/subcl 
hypo/subcl hyper/overt 
hyper 
Pooled 
ORa 
(95% 
CI)  
      
All * 1.84 (1.35-2.50) 1.21 (1.02-1.43) 1 (ref) 1.27 (1.03-1.57) 1.69 (1.00-2.87) 459/2930/36081/2386/306 
Sex       
Male 2.45 (1.45-4.12) 1.27 (1.03-1.57) 1 (ref) 1.19 (0.95-1.49) 1.59 (0.80-3.14) 122/1029/17546/1055/102 
Female 1.79 (1.30-2.47) 1.23 (0.99-1.52) 1 (ref) 1.42 (1.11-1.81) 1.78 (0.99-3.21) 337/1901/18535/1331/204 
Age       
<50 
yearse 
2.25 (1.10-4.60) 1.15 (0.77-1.74) 1 (ref) 1.27 (0.73-2.21) 3.53 (0.26-48.39) 48/452/6763/599/27 
50-65 
years 
5.53 (0.93-
33.03) 
1.44 (0.94-2.21) 1 (ref) 1.88 (1.09-3.24) 4.71 (1.25-17.78) 132/677/9719/670/63 
65-80 
years 
2.02 (1.02-3.99) 1.40 (1.10-1.78) 1 (ref) 1.21 (0.85-1.73) 1.49 (0.89-2.51) 215/1711/16814/949/186 
>80 
years 
1.91 (1.01-3.62) 1.03 (0.68-1.54) 1 (ref) 1.49 (0.99-2.23) 2.66 (0.35-20.26) 65/234/2646/168/27 
Ethnicity       
Whitef 1.97 (1.37-2.82) 1.29 (1.11-1.51) 1 (ref) 1.30 (1.04-1.63) 1.56 (1.03-2.34) 431/2687/34154/2339/303 
Blackb 0.96 (0.20-4.58) 1.51 (0.74-3.05) 1 (ref) 0.77 (0.31-1.89) - 12/98/1013/35/2 
Asianc 2.01 (0.63-6.39) 0.87 (0.54-1.39) 1 (ref) 0.82 (0.10-6.83) - 13/143/828/8/1 
Otherd - - 1 (ref) - - 0/0/22/1/0 
*P for trend; overt hyperthryroidism to euthyroidism p=0.01; euthyroidism to overt hyperthyroidism p=0.04 
ǂ P value for interaction (p<0.05) 
aResults were obtained by logistic regression analysis, adjusted for age (if applicable) and sex 
bOnly data from CHS, HABC and PREVEND 
cOnly data from LASA, Nagasaki, PREVEND and Rotterdam 
dOnly data from LASA, PREVEND and Rotterdam 
eReference group is <50 years 
fReference group is White 
Table 3. The risk of developing anemia during follow-up according to thyroid hormone status 
at baseline (N = 25 466 from 14 cohorts). 
 Overt 
hypothyroidism 
Subclinical 
hypothyroidism 
Euthyroidism Subclinical 
hyperthyroidism 
Overt 
hyperthyroidism 
N overt hypo/subcl 
hypo/subcl hyper/ overt 
hyper 
Pooled 
HRa 
(95% 
CI) 
      
All * 1.38 (0.86-2.20) 1.18 (1.00-1.38) 1 (ref) 1.15 (0.94-1.42) 1.47 (0.91-2.38) 270/1678/21965/1358/195 
Sex       
Male 2.14 (0.79-5.79) 1.05 (0.83-1.34) 1 (ref) 1.41 (0.92-2.18) 0.83 (0.26-2.61) 62/577/10450/584/63 
Female 1.19 (0.75-1.88) 1.37 (1.05-1.80) 1 (ref) 1.22 (0.95-1.57) 2.27 (1.30-3.93) 207/1096/11487/773/131 
Age       
<50 
yearse 
17.81 (4.06-
78.24) 
1.48 (0.78-2.83) 1 (ref) 1.09 (0.68-1.73) - 16/106/3857/343/21 
50-65 
years 
1.58 (0.14-
18.00) 
1.14 (0.82-1.58) 1 (ref) 1.02 (0.70-1.50) 2.97 (0.56-1 .64) 85/384/5872/414/32 
65-80 
years 
1.39 (0.81-2.37)ǂ 1.20 (0.96-1.51) 1 (ref) 1.14 (0.83-1.57) 1.51 (0.85-2.69) 130/1069/10737/521/124 
>80 
years 
1.48 (0.55-4.03)ǂ 1.30 (0.80-2.10) 1 (ref) 1.57 (0.98-2.50) 3.59 (0.49-26.06) 39/119/1499/80/18 
Ethnicity       
Whitef 1.38 (0.75-2.54) 1.21 (1.00-1.45) 1 (ref) 1.16 (0.93-1.44) 1.52 (0.93-2.50) 257/1527/20849/1336/193 
Blackb 2.80 (0.38- 1.30 (0.59-2.83) 1 (ref) 1.57 (0.57-4.36) - 5/41/415/16/1 
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20.76) 
Asianc 1.68 (0.53-5.29) 1.03 (0.70-1.51) 1 (ref) - - 6/109/654/6/1 
Otherd - - 1 (ref) - - 0/0/12/0/0 
*P for trend; overt hyperthryroidism to euthyroidism p=0.02; euthyroidism to overt hyperthyroidism p=0.20 
ǂ P value for interaction (p<0.05) 
aResults were obtained by cox regression analysis, adjusted for age (if applicable) and sex 
bOnly data from CHS, HABC and PREVEND 
cOnly data from LASA, Nagasaki, PREVEND and Rotterdam 
dOnly data from LASA, PREVEND and Rotterdam 
eReference group is <50 years 
fReference group is White 
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